“Strictly speaking, we do not view the Covid-19 epidemic as a driving force in the e-health market. However, it clearly shows that tomorrow’s healthcare is more and more going to rely on health data, not only for epidemiology but also for clinical research and patient follow-up issues.”
“We invest exclusively in companies that manage or generate health data. It is mainly software publishers usually used by hospitals and healthcare professionals, but also developed to improve the patient care pathway or to support home-care monitoring. This market is really deep and totally underestimated: in France, it is currently estimated at €4 billion against €2 billion in 2012.”
“We are particularly seeing to it that our portfolio companies excel in their core business, which is software development. […] We are also working thoroughly on the international expansion of our portfolio companies as we believe the French market players’ future is at least at the European level.”
Edouard Lacoste Lagrange, article published in Private Equity Magazine n°155, p.40-41